Advertisement

 

 

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.

Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Author Information (click to view)

Wangpatharawanit P, Sungkanuparph S,


Wangpatharawanit P, Sungkanuparph S, (click to view)

Wangpatharawanit P, Sungkanuparph S,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016 07 1163(6) 818-20 doi 10.1093/cid/ciw395

Abstract

A randomized controlled trial was conducted among human immunodeficiency virus-infected patients receiving lopinavir/ritonavir-based regimens with hypercholesterolemia. Reduction of total cholesterol and low-density lipoprotein was significantly greater in patients who were randomized to the addition of atorvastatin compared with those who were switched from lopinavir/ritonavir to atazanavir/ritonavir.

Submit a Comment

Your email address will not be published. Required fields are marked *

four × one =

[ HIDE/SHOW ]